Understanding and harnessing the graft-versus-leukaemia effect.
about
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectCancer vaccines and T cell therapyNovel therapeutic options in Acute Myeloid LeukemiaT Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical OutcomeLeukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation.Comparison of immune recovery in recipients of unmanipulated vs T-cell-depleted grafts from unrelated donors in a multicenter randomized phase II-III trial (T-cell depletion trial)Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Transplantation immunology: solid organ and bone marrow.Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia.Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplantHuman mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation.Clinical and biological predictors of outcome following relapse of CML post-allo-SCTInfluence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.Th17 mediated alloreactivity is facilitated by the pre-transplant microbial burden of the recipient.Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donorsCTLA-4 polymorphisms and haplotype correlate with survival in ALL after allogeneic stem cell transplantation from related HLA-haplotype-mismatched donorMaintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in miceImmunotherapy prospects for acute myeloid leukaemia.Unravelling the complexity of cancer-immune system interplay.Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.Relapse after allogeneic stem cell transplantationAt the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation.Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivoAllogeneic bone marrow grafts with high levels of CD4(+) CD25(+) FoxP3(+) T cells can lead to engraftment failure.The progress and current status of immunotherapy in acute myeloid leukemia.Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.Histamine H2 Receptor in Blood Cells: A Suitable Target for the Treatment of Acute Myeloid Leukemia.Immunotherapy with natural killer cells: a possible approach for the treatment of Acute Myeloid Leukemia also in Brazil.Expression of CD94 by -differentiated NK cells correlates with the and acquisition of cytotoxic featuresEarly CD8+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT
P2860
Q26770391-9CC5ADDB-DAED-4FC8-8372-4F32CF74D6BAQ26826830-F1D69A16-EBEA-4FA4-8914-1B2A19A52F37Q26995638-9996E736-C7A4-4B9D-B799-ACAAAA3742BBQ28069889-10D3FF24-98E2-48DC-A9EC-703CE1DCAD0CQ28072227-403A9699-2B30-477C-AB43-4567D33DF27DQ33558780-2B348635-3B83-4C4B-8932-8F97C1AFB749Q33722678-1A02E498-A000-4A63-A6B9-1527A5C7DF2CQ33731422-029EDDF0-292A-4C32-94BE-7938423DC108Q33770125-1E108FB4-D953-402D-B4DB-30988CBAF9BEQ33803804-F7AD70B5-9271-46BC-A35B-C76DFEA2FCE8Q33996358-A88A37E9-C18A-4509-B183-23E946911F60Q34228613-B5D7DBC1-48EE-45E2-BE1F-F73A19C76E49Q34635978-5238D5B2-5E0E-4FBE-98F6-D72FCA37CC3AQ35007600-041DFD94-BD76-4FB0-97F0-2810C92A0906Q35054717-8912663C-A237-43F8-9C81-A82DCB57C000Q35112269-F4D22A4B-189C-42A7-AC8D-ECD2EFD45802Q36321016-79465341-7CBA-4BBA-8151-FB3F9F3CFDA2Q36574519-995FF72F-C8D7-4A9D-B24E-5EBFD587B340Q36775731-7991946C-E81B-426B-8BA8-618E55686204Q36842615-DF66D0BD-5285-4F06-BE2C-5987E75DF259Q37564774-06BF755D-D657-4AA8-A666-0D1CC800C0D6Q37585018-0C456CE1-4B2E-4B00-886C-7FD18164A48AQ37763280-313B235C-CC5C-4D14-9924-64F48709F24FQ37765590-001943B7-4D23-47AF-99E7-B0CC44AA9CE1Q37810098-F4E0F673-16AC-480D-88CA-519584FD62DFQ37810125-6F3423D5-C70F-46A0-A2E0-8CEA011BB77DQ38149725-A37A6194-B15F-41F3-AA0F-8B80D5745E7CQ40085103-F9CAC6C8-8154-417D-BE8A-751089A890F1Q40657274-14C4FF6C-E29F-4C94-AD8F-9E21854A84C5Q41757334-119E1891-EFB9-413F-B13B-3F980DCBF4F2Q41997533-1FA180F7-E6EB-465A-A4AA-6999C7144A81Q44852729-DF800C76-46B1-403C-B34A-6A38A04EC775Q47590707-43A3C9E8-BF87-4C2E-852A-61278B2F2D89Q50708752-5088515F-A8BE-458B-89F9-9620008C5F34Q51696870-C399B36E-E482-48C8-9488-F91BD5033DC9Q52776174-182FFACE-6703-469D-908C-066B52D4BF6BQ58125336-1B4CCA10-1C14-49CD-8782-416DEA68E33FQ58713268-D1AB4028-0997-4BE3-B6FE-1B276FAD8E85
P2860
Understanding and harnessing the graft-versus-leukaemia effect.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Understanding and harnessing the graft-versus-leukaemia effect.
@en
Understanding and harnessing the graft-versus-leukaemia effect.
@nl
type
label
Understanding and harnessing the graft-versus-leukaemia effect.
@en
Understanding and harnessing the graft-versus-leukaemia effect.
@nl
prefLabel
Understanding and harnessing the graft-versus-leukaemia effect.
@en
Understanding and harnessing the graft-versus-leukaemia effect.
@nl
P2860
P1476
Understanding and harnessing the graft-versus-leukaemia effect.
@en
P2093
A John Barrett
P2860
P304
P356
10.1111/J.1365-2141.2008.07260.X
P407
P577
2008-06-28T00:00:00Z